Our study confirms a direct and equivalent cell-cycle inhibitory and cytotoxic effect of enzalutamide on AR-expressing vascular endothelial cells as reported on prostate cancer cells, which is reinforced by its observed capacity to inhibit vascular tubule formation in vitro. This evidence concerns the gene AR and prostate carcinoma.